CatalystWireBeta

Acquisition of Hypothesis Group, LLC

In brief · summary, not quotable

No summary for this filing – the full text is below.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your ELIX notes

Elixirr International plc (AIM: ELIX) ("Elixirr", the "Company" and together with its subsidiaries, the "Group"), the established, global award-winning challenger consultancy, is pleased to announce the acquisition by its US subsidiary, Elixirr Inc. of all of the issued and outstanding membership interests of Hypothesis Group, LLC ("Hypothesis") for a maximum consideration payable of US$45.0m (the "Consideration") (the "Acquisition").

The Board is also pleased to update its guidance for the financial year ending 31 December 2024 ("FY24") to reflect its current expectation including c.2 months' impact of the Acquisition. The Board's current expectation is that full year FY24 revenue will be in the range of £108m - £111m. Our previous Adjusted EBITDA margin guidance for FY24 of 27-29% is maintained, inclusive of the dilutive effect of Hypothesis' lower EBITDA margin at acquisition.

Acquisition highlights

  • Hypothesis is a US-based insights and strategy firm founded in 2000. Its 60+ personnel are specialised in research, strategic insights and design and have experience supporting some of the world's largest and best-known brands as strategic thought partners.
  • Hypothesis has an impressive roster of premium clients, the majority of which it has had a relationship with for over a decade. The firm's top clients include five of the Magnificent Seven mega cap technology companies, highlighting the importance and quality of Hypothesis' offering. Their client-list overall consists of multiple Fortune 500 companies, offering an exciting cross-sell opportunity for Elixirr.
  • The Acquisition is the Group's sixth since its IPO in July 2020 and reflects Elixirr's commitment to its programmatic acquisition strategy. It is the Group's fourth acquisition in the US and Hypothesis' strong US presence and excellent reputation will add immediate scale as well as help to accelerate Elixirr's growth in the region.
  • In the 12 months to August 2024 (unaudited), Hypothesis recorded revenue of US$28.1m, normalised EBITDA of US$5.1m and normalised profit before tax of US$5.0m.
  • The transaction is immediately earnings-enhancing.
  • The Acquisition brings specialist expertise in qualitative research, quantitative research and strategic insights, complementing the Group's existing service offerings and enhancing the Elixirr Group's ability to support clients from initial research and discovery through to strategy definition and delivery.
  • In addition to an expansion of capabilities, Hypothesis has deep expertise in additive industries for Elixirr, particularly as a result of its significant presence in the technology, media and entertainment, and retail and CPG industries.
  • During due diligence and client interviews, Hypothesis was found to be rated 17% better than their competition and scored higher than competitors across 11 of 14 performance categories. Together with Hypothesis, Elixirr will be able to enhance its existing service offering to its global client base, providing additional services that are highly complementary to Elixirr's established strategy, digital, data, AI and innovation offering.
  • The Group has already worked closely alongside Hypothesis on a client engagement prior to the Acquisition, validating the cross-sell potential of our combined proposition. This engagement involved conducting research to inform the brand strategy for a UK-based wealth and insurance client.
  • The US acquisition goodwill will be tax-deductible, resulting in an estimated tax benefit of US$7.5m-$10m to be realised over 15 years.

Information on Hypothesis and reasons for the Acquisition

Hypothesis helps companies to better understand their customers by providing insights, competitor intelligence and strategic advice to inform the design of products and services. Its offering includes quantitative research, qualitative research, advanced analytics, strategic brand and marketing services and consulting and design. Its "mixed methodology" approach integrates qualitative and quantitative capabilities in a single engagement to combine human insights with large-scale data analysis - an approach that is viewed as a key differentiator by clients. Through its dual focus on providing high-quality research and insights whilst being a strategic thought partner for clients, Hypothesis differentiates itself from competitors in the market. This distinctive positioning is a key reason for the Acquisition, especially when viewed in conjunction with Elixirr's complementary expertise in strategy, digital, data, AI and innovation. Hypothesis and Elixirr joining forces will benefit both firms' respective client bases, and through combining the complementary capabilities, industries and geographies of both businesses, even greater value can be delivered to clients.

Hypothesis was co-founded by Maria Stark and Jeff Seltzer in 2000. Both founders have been operationally removed from the business for several years, and the firm has been led by Maria Vallis as Hypothesis CEO since 2022, along with her management team. Maria Stark and Jeff Seltzer are both formally exiting the business with this transaction, but will retain shares in the Elixirr Group. Maria Vallis will join the Group as an Elixirr Partner.

Consideration for the Acquisition

The Group is acquiring Hypothesis for a maximum consideration payable of US$45.0m, with customary adjustments for net cash / debt and working capital at Closing. The firm's founders have not been involved in the business for several years, and therefore Elixirr's typical three-year deferred consideration structure has not been applied to this transaction. This has been replaced through incentivising Maria Vallis, CEO, and her management team with market-priced options packages that only vest on achieving revenue and EBITDA growth targets for Hypothesis over three years. The consideration for the Acquisition consists of:

  • Initial consideration of US$37.3m, of which, US$28.9m has been settled from Elixirr's existing cash balances and revolving credit facility;
  • US$8.4m to be settled through the issuance of 914,604 new Ordinary Shares in the Company at a price per share of £7.00;
  • Deferred consideration of up to US$7.6m in cash, the majority of which will be payable in FY25 in relation to FY24 EBITDA performance with the balance payable in FY26 after the expiry of certain indemnities; and
  • Adjustment for net cash / debt and working capital at Closing to be settled in FY25.

Based on the target's EBITDA for the past twelve months, this constitutes a day 1 EV/EBITDA multiple of 7.3x, and a maximum EV/EBITDA multiple of 8.8x if all deferred consideration is payable.

The new Ordinary Shares will be subject to one-year lock-in arrangements and limitations on the Ordinary Shares that each founder seller can sell in each of the following three years under nominee agreements.

Maria Vallis to join as Elixirr Partner

Hypothesis CEO Maria Vallis joins the Group as an Elixirr Partner, with incentives aligned to the growth of Hypothesis' revenue and EBITDA over the three years post-acquisition. These incentives will ensure the continued motivation of Hypothesis management. In line with other Elixirr Partners, Maria will purchase Ordinary Shares equal to a value of £500,000 from the EBT at the Company's closing share price on 21 October. The Ordinary Shares will be subject to a one-year lock-in arrangement and limitations on the Ordinary Shares that Maria Vallis can sell in each of the following four years under a nominee agreement.

Admission and Total Voting Rights

As referred to above, Elixirr will issue 914,604 Ordinary Shares ("New Shares"). The New Shares will rank pari passu with the Company's existing issued Ordinary Shares. The New Shares will be issued pursuant to the Company's existing outstanding shareholder authorities. Application will be made to the London Stock Exchange for the New Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8.00 a.m. on 25 October 2024.

After Admission, the total number of Ordinary Shares in issue will be 48,187,415 and the total number of voting rights will therefore be 48,187,415. Following Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Founder & CEO of Elixirr, Stephen Newton said:

"We first met the Hypothesis team about 18 months ago, and the opportunity to join forces has consistently excited us ever since those very first discussions. With our challenger DNA and focus on high performance, both Elixirr and Hypothesis are premium brands that work with premium clients. The acquisition will further solidify the strong reputation we've been building and bring rigour to our research and insights offering. We're excited to welcome Maria Vallis to the Partner team as we accelerate our growth in the US. Her esteemed reputation - trusted by a high calibre of clients across additive and complementary industries - will make her a great addition to the team. Maria and Hypothesis' expertise will help us solidify the strong reputation we've been building in the US market, which remains a key priority for us."

CEO of Hypothesis, Maria Vallis said:

"The Hypothesis team is excited to join forces with the Elixirr Group as we're now able to take our insights and recommendations further and can do more to solve our clients' business issues. Considering that Hypothesis was founded with the goal of disrupting the research and insights industry, it was important to us to join a firm who had similar ethos. We believe that we have found this with Elixirr. The combination of capabilities between Hypothesis and the Elixirr Group is really powerful and will enable us to deliver even more impact to our collective client base. Elixirr's strong expertise across different verticals, including financial services, healthcare and insurance, alongside the ability to add strategy, digital, data, AI and innovation capabilities to our skillset is really exciting to us and we look forward to seeing what our teams can accomplish together."

Co-Founders of Hypothesis, Maria Stark and Jeff Seltzer said:

"Nearly 25 years ago, we started a new kind of agency that embraced creativity and empowered our people to do great work for great clients. We're extremely proud of what we built, and what we accomplished with the help of the industry's best and brightest people. It's been incredible to watch the next generation of Hypothesis leadership evolve and grow the company while still embracing our original founding vision. Today, the transition is complete, and we're truly excited to watch Hypothesis and Elixirr disrupt and challenge the industry, and to continue helping the world's best brands do amazing things."

General

All references to time in this announcement are to London time, unless otherwise stated.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note